MeSH term
Frequency | Condition_Probility | Acute Disease | 5 | 0.0 |
Adult | 16 | 0.0 |
Comparative Study | 17 | 0.0 |
Humans | 108 | 0.0 |
Animals | 41 | 0.0 |
Homeostasis | 4 | 1.0 |
Models, Biological | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 78 | 0.0 |
Base Sequence | 8 | 0.0 |
Calcium Signaling/physiology | 2 | 5.0 |
DNA Primers | 2 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Ligands | 7 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
Signal Transduction | 2 | 0.0 |
Transfection | 6 | 0.0 |
*Chemotaxis, Leukocyte | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
T-Lymphocyte Subsets/cytology/immunology/metabolism | 2 | 16.0 |
Male | 20 | 0.0 |
Middle Aged | 13 | 0.0 |
Antigens, CD/metabolism | 3 | 0.0 |
Immunologic Memory | 11 | 3.0 |
Infant | 2 | 0.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Mice | 27 | 0.0 |
Mice, Inbred C57BL | 10 | 0.0 |
Cell Differentiation | 8 | 0.0 |
Receptors, Chemokine/*analysis | 5 | 13.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Cell Adhesion | 4 | 0.0 |
Cells, Cultured | 23 | 0.0 |
Dendritic Cells/immunology | 2 | 1.0 |
Endocytosis | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 4 | 1.0 |
Immunophenotyping | 6 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Lymphocyte Activation | 7 | 0.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 3 | 8.0 |
Binding Sites/immunology | 2 | 3.0 |
Calcium/metabolism | 6 | 0.0 |
Chemotaxis, Leukocyte/immunology | 2 | 3.0 |
Interphase/immunology | 2 | 4.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Cell Line | 12 | 0.0 |
Cell Movement/immunology | 3 | 3.0 |
Chemokines/metabolism | 3 | 4.0 |
Receptors, CCR5/metabolism | 3 | 2.0 |
Receptors, Chemokine/metabolism | 5 | 4.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Chemotactic Factors/pharmacology | 2 | 6.0 |
Chemotaxis/drug effects | 3 | 3.0 |
Pertussis Toxin | 2 | 1.0 |
Signal Transduction/physiology | 2 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Down-Regulation | 5 | 0.0 |
Receptors, CXCR4/metabolism | 2 | 1.0 |
Receptors, Cytokine/*metabolism | 2 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Up-Regulation | 6 | 0.0 |
ADP-ribosyl Cyclase/analysis | 2 | 9.0 |
Antigens, CD/analysis | 4 | 0.0 |
Antigens, CD19/analysis | 2 | 2.0 |
Cell Movement | 8 | 0.0 |
Lymphocyte Count | 3 | 0.0 |
Receptors, CXCR4/analysis | 3 | 8.0 |
Receptors, Cytokine/analysis | 3 | 20.0 |
Chemokines, CC/*genetics | 2 | 6.0 |
Macrophage Inflammatory Proteins/*genetics | 2 | 40.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Receptors, Chemokine/analysis | 4 | 13.0 |
*Transcription, Genetic | 2 | 0.0 |
Chemotaxis | 11 | 6.0 |
Flow Cytometry | 20 | 0.0 |
Cell Lineage | 2 | 0.0 |
Female | 22 | 0.0 |
Gene Targeting | 2 | 0.0 |
Green Fluorescent Proteins | 4 | 0.0 |
Receptors, Chemokine/*genetics | 4 | 4.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Kinetics | 2 | 0.0 |
Receptors, Chemokine/*biosynthesis/genetics | 4 | 13.0 |
DNA, Complementary/genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Receptors, Chemokine/genetics | 2 | 4.0 |
Cell Division | 2 | 0.0 |
Chemokines, CC/pharmacology | 3 | 9.0 |
Cytokines/pharmacology | 4 | 1.0 |
Immunohistochemistry | 8 | 0.0 |
Macrophage Inflammatory Proteins/pharmacology | 2 | 40.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Langerhans Cells/*immunology | 2 | 5.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Intestinal Mucosa/*immunology | 2 | 2.0 |
*Receptors, Chemokine | 6 | 6.0 |
Tumor Necrosis Factor-alpha/pharmacology | 6 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Chemokines, CC/genetics/metabolism/*physiology | 2 | 66.0 |
Phosphorylation | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Dendritic Cells/*immunology/metabolism | 3 | 6.0 |
Chemokines, CXC/pharmacology | 4 | 5.0 |
Phenotype | 6 | 0.0 |
Receptors, Chemokine/genetics/*metabolism | 9 | 19.0 |
Mice, Knockout | 6 | 0.0 |
Receptors, Chemokine/genetics/metabolism/*physiology | 3 | 50.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Gene Expression | 4 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Dimerization | 3 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Chemokine/*metabolism | 5 | 3.0 |
B-Lymphocytes/chemistry | 2 | 8.0 |
Combined Modality Therapy | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Receptors, Chemokine/physiology | 2 | 7.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
*Chemokines, CC | 5 | 6.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
CD4-Positive T-Lymphocytes/physiology | 3 | 5.0 |
CD8-Positive T-Lymphocytes/physiology | 2 | 8.0 |
Receptors, Chemokine/*genetics/metabolism | 2 | 14.0 |
Adolescent | 3 | 0.0 |
Aged | 7 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
*Cell Movement | 2 | 1.0 |
Chemokines, CC/metabolism | 2 | 4.0 |
In Vitro | 3 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Chemokines/pharmacology | 2 | 6.0 |
Receptors, Chemokine/genetics/*isolation & purification | 2 | 100.0 |
Chemokines/*immunology | 3 | 15.0 |
*Immunity, Cellular | 2 | 1.0 |
Receptors, Chemokine/immunology | 3 | 9.0 |
Cell Movement/*immunology | 2 | 2.0 |
Chemokines, CC/physiology | 2 | 15.0 |
*Immunologic Memory | 3 | 2.0 |
*Macrophage Inflammatory Proteins | 10 | 62.0 |
Stress, Mechanical | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology/*metabolism/pathology | 2 | 100.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Gene Expression/drug effects | 2 | 0.0 |
Interferon Type II/pharmacology | 4 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Lymphoid Tissue/cytology | 2 | 9.0 |
Plasma Cells/cytology | 2 | 33.0 |
Luminescent Proteins/biosynthesis/genetics | 2 | 8.0 |
Sequence Deletion | 2 | 0.0 |
Chemotaxis, Leukocyte/*drug effects | 2 | 3.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
RNA/analysis | 2 | 0.0 |
Time Factors | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Cell Movement/*physiology | 2 | 0.0 |
Macrophage Inflammatory Proteins/*physiology | 2 | 66.0 |
Chemokines, CC/metabolism/pharmacology | 6 | 37.0 |
Recombinant Proteins/metabolism/pharmacology | 2 | 1.0 |
Binding, Competitive | 2 | 0.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Chemokines/*physiology | 4 | 12.0 |
Receptors, Chemokine/*biosynthesis/physiology | 2 | 22.0 |
Infant, Newborn | 2 | 0.0 |
Receptors, CCR5/genetics | 2 | 3.0 |
Receptors, Lymphocyte Homing/metabolism | 2 | 5.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Neoplasm Staging | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Kidney | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
RANTES/pharmacology | 2 | 3.0 |
Case-Control Studies | 3 | 0.0 |
Prognosis | 2 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Chemokines, CC/*physiology | 2 | 14.0 |
Amino Acid Sequence | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Dendritic Cells/immunology/metabolism | 2 | 11.0 |
Inflammation/immunology/metabolism | 2 | 11.0 |
Postoperative Period | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Mutation | 2 | 0.0 |
Arthritis, Rheumatoid/*metabolism/pathology | 2 | 5.0 |
Receptors, Chemokine/*physiology | 2 | 4.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
Biological Markers/analysis | 3 | 0.0 |
Cell Migration Inhibition | 2 | 1.0 |
Cell Movement/physiology | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Chemokines, CC/analysis | 2 | 18.0 |
Macrophage Inflammatory Proteins/analysis | 2 | 100.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Macrophage Inflammatory Proteins/metabolism/pharmacology | 2 | 66.0 |
